



**EIKO LIFESCIENCES LIMITED**

F E E L T H E C H E M I S T R Y

Ref. No.: EIKO/BSE/2023-24/50

**Date:** 25<sup>th</sup> January, 2024

To,  
Corporate Services Department,  
**BSE Limited**,  
P J Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

**Scrip Code:** 540204

**Sub: Business Update - Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements), 2015. We wish to inform you that the Company has entered into agreement with Vivacious Pharmatex Pvt. Ltd. (VPPL) to further strengthen market position and to develop new products, commercialization, and marketing at our manufacturing facilities.

A Detailed update on this have been marked as **Annexure A**.

Please take the same on your record.

Thanking you,

For **EIKO LIFESCIENCES LIMITED**

---

**Jaid Kojar**  
**Chief Financial Officer**



## Business Update

We are pleased to update that as of January 25, 2024, Eiko LifeSciences Ltd. (ELL) has officially entered into a definitive business agreement with Vivacious Pharmatex Pvt. Ltd. (VPPL) (now under a new management), a move that holds immense potential for our company's growth and strategic positioning. This strategic decision involves the sale and transfer of our minority stake in VPPL, paving the way for a dynamic collaboration under the leadership of VPPL's new and experienced management.

Over the past few months, extensive deliberations and discussions have culminated in the signing of a definitive agreement with VPPL. This marks a strategic expansion for ELL into the "**Oleochemicals and Allied Business**" segment, a domain integral to products in personal care, pharmaceuticals, agrochemicals, paints, coatings, fragrance, polymer, and petrochemicals.

As part of this venture, ELL is committed to investing Rs. 8 Crore over the next year, underscoring our confidence in the substantial benefits that will accrue from this strategic partnership. Furthermore, our status as the preferred business partner for VPPL in terms of sourcing and supplying key raw materials positions us advantageously in the market.

The agreement itself is structured for an initial period of a minimum of 3 years, with the potential for extension based on mutually agreed terms and conditions. In addition to the business collaboration, VPPL, under the leadership of the new management, will provide full cooperation in developing new products, commercialization, and marketing at our manufacturing facilities.

Importantly, ELL stands to gain from the vast knowledge, expertise, and research and development skills of the new management at VPPL. This collaboration is poised to be synergistic, ensuring innovation, growth, and success for both ELL and VPPL.

We are confident that our investors will recognize the strategic significance of this move, and we look forward to your continued support as we embark on this exciting phase of our company's journey.

For more information on the Company, please log on to [www.eikolifesciences.com](http://www.eikolifesciences.com)

\*\*\*\*\*